Mechanism of action of aragusterol A (YTA0040), a potent anti-tumor marine steroid targeting the G1 phase of the cell cycle

International Journal of Cancer

Volumn 88, Issue 5, 2000, Pages 810-819

  Fukuoka, Kazuya ^a,d   Yamagishi, Takehiro ^b   Ichihara, Tomoko ^b   Nakaike, Shiro ^b   Iguchi, Kazuo ^c   Yamada, Yasuji ^c   Fukumoto, Hisao ^a   Yoneda, Takahiro ^d   Samata, Kazunori ^b   Ikeya, Hisao ^b   Nanaumi, Kayoko ^b   Hirayama, Noriko ^b   Narita, Nobuhiro ^d   Saijo, Nagahiro ^a   Nishio, Kazuto ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b TAISHO PHARMACEUTICAL CO LTD   (Japan)

^c TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^d NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARAGUSTEROL A; CISPLATIN; CYCLIN A; PROTEIN P53; UNCLASSIFIED DRUG; YTA 0040;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; CROSS RESISTANCE; DOSE RESPONSE; DOWN REGULATION; DRUG MECHANISM; DRUG STRUCTURE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LEUKEMIA CELL; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SYNTHESIS; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; CELL DIVISION; CYCLIN-DEPENDENT KINASES; CYCLINS; DNA; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; G1 PHASE; HUMANS; LEUKEMIA P388; LUNG NEOPLASMS; MACROMOLECULAR SUBSTANCES; MICE; PHOSPHORYLATION; PORIFERA; PROTO-ONCOGENE PROTEINS P21(RAS); RETINOBLASTOMA PROTEIN; STEROIDS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034569844     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(20001201)88:5<810::AID-IJC20>3.0.CO;2-P     Document Type: Article

References (30)

1. 1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A 431 cells
2. 2+ stores, phosphorylation of elF2 alpha, and sustained inhibition of translation initiation mediate the anti-cancer effects of clotrimazole
3. 1 phase by specific inhibitor on CDK2 kinase activity
4. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
5. 1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells
6. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
7. 1 cyclin expression in normal rat kidney cells by inostamycin, a phosphatidylinositol synthesis inhibitor
8. A phase I trial of the spicamycin analogue KRN5500
9. Establishment and characterization of cisplatin-resistant sublines of human lung cancer cell lines
10. Cyclins and cancer II: Cyclin D and CDK inhibitors come of age
11. Aragusterol A: A potent antitumor marine steroid from the Okinawan sponge of the genus Xestospongia
12. Neuronal differentiation of neuro 2a cells by inhibitors of cell cycle progression, trichostatin A and butyrolactone I
13. Inhibition of cyclin D1 expression and phosphorylation of retinoblastoma protein by phosmidosine, a nucleotide antibiotic
14. Anti-tumor activity of a spicamycin derivative, KRN 5500, and its active metabolite in tumor cells
15. UCN-01, 7-hydroxy-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell lines
16. A cyclin-dependent kinase inhibitor, butyrolactone I, inhibits phosphorylation of Rb protein and cell cycle progression
17. Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinase
18. In vitro cytotoxicity of a novel antitumor antibiotic, spicamycin derivative, in human lung cancer cell lines
19. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk 2, and cdk5
20. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
21. cis-Diamminedichloroplatinum (II) inhibits p34(cdc2) protein kinase in human lung-cancer cells
22. Mutations in the p16(INK4)/MTS1/CDKN2, p15(IN4KB)/MTS2, and p18 genes in primary and metastatic lung cancer
23. Chemical characterization and biological activity of an anticancer agent of marine origin
24. 1 arrest at two points: Effect on retino-blastoma protein phosphorylation and cyclin-dependent kinase 2 in normal and transformed cells
25. Cell cycle arrest and inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells
26. Cancer cell cycles
27. The geranylgeranyltransferase I inhibitor GGTI-298 induces hypophosphorylation of retinoblastoma and partner switching of cyclin-dependent kinase inhibitors. A potential mechanism for GGTI-298 antitumor activity
28. 1 phase of the cell cycle
29. The retinoblastoma protein and cell cycle control